Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics
Emendo Biotherapeutics, a leader in next-generation gene editing using synthetic biology to address untreatable diseases, today announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-based biopharma, reflecting its strategic interest in partnering with Emendo on the development of specific indications.
“This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases,” said Dr. David Baram, President & CEO, Emendo Biotherapeutics. “We are grateful for such strong support from so many high-quality investors and strategic partners including AnGes, OrbiMed Advisors, OrbiMed Israel Partners and Takeda Ventures who share our vision to translate this powerful science into transformative medicines.”
Emendo Biotherapeutics is pioneering OMNI, a next-generation allele-specific gene editing platform that uses synthetic biology to expand what is possible in genome-editing. In 2019, Emendo granted an option to Takeda to use the OMNI nuclease gene editing program for two research and development targets. Emendo received an undisclosed investment from Takeda Ventures that was converted in the Series B.
Emendo’s OMNI technology enables precision gene editing while maintaining high efficiencies, uniquely addressing dominant indications such as Severe Congenital Neutropenia (SCN), caused by mutations in the neutrophil elastase gene ELANE. Dominant indications represent the vast majority of genetic diseases which until now have been untreatable.
About AnGes
AnGes is a Tokyo and Osaka, Japan-based biopharmaceutical company focused on the development and commercialization of gene-based medicines including gene therapy and oligonucleotide molecules. AnGes’ lead product HGF plasmid, which received conditional approval in Japan in 2019, is a DNA plasmid which encodes the human Hepatocyte Growth Factor (HGF) gene, an angiogenic (new blood vessel growth) factor for critical limb ischemia (CLI). The company is also developing NF-kB Decoy oligonucleotide for the treatment of inflammatory diseases. For more information please visit www.anges.co.jp.
About Emendo
Emendo Biotherapeutics is transforming the landscape of genome-editing based medicine through its use of novel CRISPR nucleases, advanced cutting-edge protein engineering platforms, diverse pipeline of clinical programs and extensive intellectual property portfolio. For more information please visit us at www.emendobio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005379/en/
Contact information
Julie Amar
info@emendobio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uptime Institute Announces Five Data Center Predictions Report for 202613.1.2026 13:04:00 EET | Press release
Uptime Institute today announced the release of its Five Data Center Predictions for 2026 looking beyond the more obvious trends of 2026 and examining some of the latest developments and challenges shaping the digital infrastructure industry. The 2026 predictions focus on the continued growth of the industry and related challenges, while also recognizing AI as a powerful, transformative accelerant to growth. While AI is the key driver for a wave of investment that will underpin digital infrastructure for decades to come, the speed and ultimate size of the build-outs are unclear at this time. “Critical digital infrastructure continues to expand strongly,” said Andy Lawrence, Executive Director of Research, Uptime Institute. “At the same time, our research shows uncertainty about how AI will reshape demand. This is complicating both capacity planning and resiliency strategies. We are also seeing increasing fragmentation in the design and deployment of data centers and expect investment a
BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research13.1.2026 13:00:00 EET | Press release
BlueMatrix, the global leader in capital markets content publishing technology, backed by Thoma Bravo, today announced a partnership with Perplexity to bring AI-enabled research and discovery to institutional investors using BlueMatrix’s governed, entitlement-aware framework. The partnership brings entitled broker research to Perplexity Enterprise users, enabling buy-side professionals to query their subscribed research content, alongside Perplexity’s broader capabilities, including real-time financial data, earnings transcripts, and deep research tools. Investment professionals and researchers can use natural language to surface relevant insights without changing existing data ownership, entitlements, or compliance structures. As buy-side teams increasingly turn to AI tools for research synthesis, a formal integration through BlueMatrix replaces unstructured, ungoverned usage with compliant distribution that preserves attribution and entitlements. For research firms, the partnership p
BeOne Medicines Highlights Global Oncology Leadership at 44 th Annual J.P. Morgan Healthcare Conference13.1.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton’s tyrosine kinase (BTK) inhibitors, as well as foundational hematology assets: sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor that received its first global regulatory approvals on December 30, and BGB-16673, a potentially first-in-class and best-in-class BTK chimeric degradation activation compound (CDAC). In addition, Mr. Oyler will share further information on BeOne’s global development superhighway, which encompasses global, wholly internal, and competitively advantaged
Vaudoise Becomes First Swiss Insurer to Go-Live with Guidewire Cloud Platform13.1.2026 12:21:00 EET | Press release
Vaudoise and Guidewire (NYSE: GWRE) have announced that Vaudoise has become the first Swiss insurer to go-live on Guidewire Cloud Platform. The company has successfully implemented Guidewire ClaimCenter and is currently integrating Guidewire PolicyCenter. By adopting Guidewire Cloud Platform, Vaudoise joins a global community of insurers focusing on insurance excellence with core modernization from a scalable, secure and rapidly updatable cloud delivery model. Arno Suess, Head of P&C Claims at Vaudoise, said: “We are very proud of this milestone, which sets a new benchmark for our industry. With Guidewire Cloud Platform, we can now process motor insurance claims faster, with greater automation and fully digital processes. The result: faster decisions, more transparency, and a seamless experience for customers during critical moments in their lives.” Mathias Grobet, EMEA VP at Guidewire, said: “Vaudoise is well-known for its customer focus, operational excellence and agility – qualities
Ant International Powered Over 2 Billion Transactions in its Core Emerging Markets in 2025, Expanding AI Payments and Digital Commerce Tools for Inclusive Growth13.1.2026 12:15:00 EET | Press release
Ant International supported over 2 billion digital cross-border transactions in 2025 for merchants in its core emerging markets including Southeast Asia (SEA), South Asia, the Middle East and Latin America (LATAM), as the company builds out a broader range of AI-powered digital financial and commerce solutions tailored to these regions’ diverse needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113850175/en/ Alipay+ now connects more than 1.8 billion user accounts across 40 international payment partners to merchants across more than 100 markets Ant International is focused on improving access to payments, credit, digital banking and cross-border connectivity in fast-growing but fragmented digital economies. The company currently serves more than 150 million merchants globally, 90% of which are SMEs. “In the world’s fastest growing emerging markets, real-world, trusted and scalable adoption of AI and other new technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom